Funding for this research was provided by:
Scientific and Innovative Action Plan of Shanghai (20ZR1411300)
National Natural Science Foundation of China (91332201)
National Key Research and Development Program Foundation of China (2016YFC1306403)
Zhongshan Hospital Science Foundation (2018ZSQN28)
Received: 6 May 2020
Accepted: 24 September 2020
First Online: 20 October 2020
Ethical approval and consent to participate
: All animal care and experimental procedures were carried out according to the guidelines of the Animal Care Committee of Fudan University. This study was approved by Medical Experimental Animal Administrative Committee of Fudan University, and the committee on medical ethics of Zhongshan Hospital, Fudan University.
: Not applicable.
: Chunjiu Zhong holds shares of Shanghai Rixin Biotech Co., Ltd., which focuses on the development of new drugs against Alzheimer’s disease. The other authors declare that he/she has no conflict of interest.